奥美拉唑在肝硬化患者中的药动学研究

 目的研究8例肝硬化患者静脉滴注奥美拉唑(OME)的药动学特性。方法采用HPLC测定血浆OME浓度，以3P97程序计算药动学参数。结果肝硬化患者静滴OME的血药浓度曲线符合二室模型，消除半衰期为(3.34±0.38)h，明显大于国内外文献报道的健康人结果，药物清除明显减慢。结论肝硬化患者应用OME时给药剂量可减半或酌情调整。

Pharmacokinetics of omeprazole in patients with liver cirrhosis

OBJECTIVE　To study the pharmacokinetics of omeprazole (OME) in 8 patients with liver cirrhosis.METHODS　The plasma concentrations of OME were determined by HPLC,and the pharmacokinetic parameters were computed by using 3P97 program.RESULTS　The plasma concentration versus time curve following intravenous 40 mg OME in patients with liver cirrhosis was coincident with two-compartment model.The elimination half-life was (3.34±0.38) h,which was longer than the value of the healthy volunteers and CLs was lower than the value of the healthy volunteers.CONCLUSION　The dosage of OME may be given in the half of the routine dosage or adjusted conditionally when using for the patients with liver cirrhosis.